Entering text into the input field will update the search result below

FDA OKs BioCryst Pharma's Orladeyo to prevent attacks in hereditary angioedema

  • The FDA has appoved BioCryst Pharmaceuticals' (NASDAQ:BCRX) oral, once-daily Orladeyo (berotralstat) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older.
  • HAE is a disorder characterized by recurrent episodes of severe swelling (angioedema). The

Recommended For You

About BCRX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
BCRX--
BioCryst Pharmaceuticals, Inc.